Holen Sie sich die Stockscreener-App
89.32
0.96%
0.85
Vorhandelsmarkt:
89.13
-0.19
-0.21%
Schlusskurs vom Vortag:
$88.47
Offen:
$88.47
24-Stunden-Volumen:
764.98K
Relative Volume:
0.75
Marktkapitalisierung:
$6.66B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-255.84M
KGV:
-21.19
EPS:
-4.2149
Netto-Cashflow:
$-232.60M
1W Leistung:
+7.46%
1M Leistung:
+24.23%
6M Leistung:
+59.93%
1J Leistung:
+171.90%
1-Tages-Spanne:
$86.07
$89.69
1-Wochen-Bereich:
$82.64
$89.69
52-Wochen-Spanne:
$31.38
$89.69
Apogee Therapeutics Inc Stock (APGE) Company Profile
Firmenname
Apogee Therapeutics Inc
Sektor
Branche
Telefon
650-394-5230
Adresse
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
89.32 | 6.60B | 0 | -255.84M | -232.60M | -4.2149 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-18 | Eingeleitet | Truist | Hold |
| 2026-01-22 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-07 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-12-17 | Eingeleitet | Stephens | Overweight |
| 2025-12-10 | Eingeleitet | Deutsche Bank | Buy |
| 2025-11-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-07 | Bestätigt | BTIG Research | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-11-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-05-10 | Eingeleitet | BofA Securities | Buy |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | Guggenheim | Buy |
| 2023-08-08 | Eingeleitet | Jefferies | Buy |
| 2023-08-08 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Apogee Therapeutics Inc Aktie (APGE) Neueste Nachrichten
Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis - MSN
APGE stock up as skin disease drug shows sustained 52-week efficacy - MSN
Apogee Therapeutics (NASDAQ:APGE) Reaches New 1-Year HighStill a Buy? - MarketBeat
(APGE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Apogee Therapeutics Insider Sold Shares Worth $1,651,664, According to a Recent SEC Filing - Moomoo
How Investors May Respond To Apogee Therapeutics (APGE) CEO Share Sale and US$403 Million Equity Raise - Sahm
Aug PreEarnings: Will Apogee Therapeutics Inc benefit from seasonalityPortfolio Return Report & Expert Approved Trade Ideas - baoquankhu1.vn
Dow Update: Should value investors consider Apogee Therapeutics IncQuarterly Market Summary & Accurate Technical Buy Alerts - baoquankhu1.vn
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) CEO Sells 20,000 Shares of Stock - MarketBeat
Apogee Therapeutics CEO Henderson sells $1.65 million in stock By Investing.com - Investing.com Australia
Apogee Therapeutics CEO Henderson sells $1.65 million in stock - Investing.com
Apogee Therapeutics (APGE) CEO sells 20,000 shares under Rule 10b5-1 plan - Stock Titan
Apogee Therapeutics stock hits all-time high at 85.95 USD By Investing.com - Investing.com Australia
Apogee Therapeutics stock hits all-time high at 85.95 USD - Investing.com
T. Rowe Price (APGE) discloses 10.29M shares, 16.8% stake in Apogee - Stock Titan
Trade Recap: Whats the beta of Apogee Therapeutics Inc stockWatch List & Fast Moving Stock Watchlists - baoquankhu1.vn
APGE Earnings History & Surprises | EPS & Revenue Results | APOGEE THERAPEUTICS INC (NASDAQ:APGE) - ChartMill
Insider Sell: Jane Henderson Sells 2,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics (APGE) CMO sells shares worth $466,619 By Investing.com - Investing.com Canada
Apogee Therapeutics (APGE) CMO sells shares worth $466,619 - Investing.com
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) Insider Sells 5,500 Shares of Stock - MarketBeat
Apogee Therapeutics (APGE) CMO trades 5,500 shares under 10b5-1 plan - Stock Titan
Responsive Playbooks and the APGE Inflection - Stock Traders Daily
APGE Technical Analysis & Stock Price Forecast - Intellectia AI
Mizuho Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation - MSN
Banque Pictet & Cie SA Invests $3.16 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics CMO sells $361,860 in shares - Investing.com
Deutsche Bank Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $118 - Moomoo
SG Americas Securities LLC Sells 60,964 Shares of Apogee Therapeutics Inc. $APGE - marketbeat.com
Fairmount Funds Management LLC Increases Stake in Apogee Therape - GuruFocus
Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week HighHere's What Happened - MarketBeat
Apogee Therapeutics prices upsized $350M offering at $70 a share - MSN
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $137 - Moomoo
APGE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Market Rankings: Will Apogee Therapeutics Inc benefit from seasonalityEarnings Recap Summary & Weekly Setup with ROI Potential - baoquankhu1.vn
Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action? - simplywall.st
BTIG reiterates Buy on Apogee Therapeutics stock, $137 target By Investing.com - Investing.com South Africa
BTIG reiterates Buy on Apogee Therapeutics stock, $137 target - Investing.com
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $110.00 at Mizuho - MarketBeat
Mizuho raises Apogee Therapeutics stock price target on AD data By Investing.com - Investing.com South Africa
Finanzdaten der Apogee Therapeutics Inc-Aktie (APGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):